{"entity":{"id":"nct05187338","kind":"trial","name":"Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ipilimumab, pembrolizumab and durvalumab in pancreatic cancer, run by Second Affiliated Hospital of Guangzhou Medical University, now recruiting.","summary":"Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT05187338 by Second Affiliated Hospital of Guangzhou Medical University, with a registry enrolment figure of 100 participants, started 2021-11-01 and due to reach its primary completion in 2029-10-30. Interventions recorded: ipilimumab +pembrolizumab +durvalumab. Conditions listed: Lung Cancer; Liver Cancer; Colorectal Cancer; Pancreas Cancer; Ovary Cancer; Head and Neck Cancer; Breast Cancer; Gastric Cancer; Cervical Cancer; Esophageal Cancer; Sarcoma. Primary outcome: Safety of 3 drugs combination treatment; Progression-free survival; Disease control rate. Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05187338","url":"https://clinicaltrials.gov/study/NCT05187338"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["ipilimumab","pembrolizumab","durvalumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05187338","phase":"1/2","setting":"Triplex CTLA4/PD1/PDL1 Checkpoint Inhibitors Combination Therapy for Advanced Solid Tumors","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","participation":[{"nct":"NCT05187338","source":"https://clinicaltrials.gov/study/NCT05187338","fetchedAt":"2026-10-07T16:53:36.501Z","studySha256":"5bed0523ebd29ca6e3015bd00fae0d9980d1a976708afa69b04497672f99fe36","overallStatus":"RECRUITING","lastUpdatePosted":"2024-06-25","leadSponsor":"Second Affiliated Hospital of Guangzhou Medical University","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"70 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":100,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2021-11-01","startedType":"actual","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05187338/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}